A BILL 
To provide for the acceleration of access to clinical therapies 
for the treatment of amyotrophic lateral sclerosis, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Accelerating Access 
4
to Critical Therapies for ALS Act’’. 
5
SEC. 2. GRANTS FOR RAPID DEVELOPMENT OF THERAPIES 
6
FOR ALS AND OTHER RAPIDLY PROGRESSING 
7
NEURODEGENERATIVE DISEASES. 
8
(a) IN GENERAL.—The Secretary of Health and 
9
Human Services shall award grants to eligible entities for 
10
20:05 Jun 20, 2020
H7071
2 
•HR 7071 IH
the provision of investigational drugs through an expanded 
1
access program pursuant to section 561 of the Federal 
2
Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb) for 
3
individuals for the prevention, diagnosis, mitigation, treat-
4
ment, or cure of amyotrophic lateral sclerosis or another 
5
rapidly progressing neurodegenerative disease. 
6
(b) VESTED AUTHORITY.—For purposes of develop-
7
ment of an investigational drug pursuant to subsection 
8
(a), the Secretary may vest authority in the participating 
9
clinical trial site or sites to make the determination under 
10
subsection (b)(2), (c)(6), or (c)(7), as applicable, of the 
11
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
12
360bbb). 
13
(c) TIMING.—Not later than 60 days after the date 
14
of submission of an application for a grant under this sec-
15
tion— 
16
(1) the Secretary, acting through the Director 
17
of the National Institutes of Health, shall determine 
18
whether to award the grant; and 
19
(2) the Secretary acting through the Commis-
20
sioner of Food and Drugs (or by vesting authority 
21
in the participating clinical trial site, as applicable) 
22
shall make the determinations required of the Sec-
23
retary under subsection (b) or (c), as applicable, of 
24
section 561 of the Federal Food, Drug, and Cos-
25
20:05 Jun 20, 2020
H7071
3 
•HR 7071 IH
metic Act (21 U.S.C. 360bbb) for the provision of 
1
the investigational drug to occur. 
2
(d) DEFINITIONS.—In this section: 
3
(1) The term ‘‘Director’’ means the Director of 
4
the National Institutes of Health. 
5
(2) The term ‘‘eligible entity’’ means an entity 
6
that is— 
7
(A) a small business concern (as defined in 
8
section 3(a) of the Small Business Act (15 
9
U.S.C. 632(a))) that is the sponsor of a drug 
10
that is the subject of an investigational new 
11
drug application under section 505(i) of the 
12
Federal Food, Drug, and Cosmetic Act (21 
13
U.S.C. 355(i)); or 
14
(B) a participating clinical trial site for 
15
such an applicant. 
16
(3) The term ‘‘participating clinical trial’’ 
17
means a phase 2 or phase 3 clinical trial conducted 
18
pursuant to an exemption under section 505(i) of 
19
the Federal Food, Drug, and Cosmetic Act (21 
20
U.S.C. 355(i)) or section 351(a) of the Public 
21
Health Service Act (42 U.S.C. 262(a)) to investigate 
22
a drug intended to treat amyotrophic lateral scle-
23
rosis 
or 
another 
rapidly 
progressing 
24
neurodegenerative disease. 
25
20:05 Jun 20, 2020
H7071
4 
•HR 7071 IH
(4) The term ‘‘participating clinical trial site’’ 
1
means a health care facility at which patients par-
2
ticipating in a participating clinical trial receive 
3
treatment through such trial. 
4
(5) The term ‘‘Secretary’’ means the Secretary 
5
of Health and Human Services. 
6
(e) FUNDING.— 
7
(1) AUTHORIZATION
OF
APPROPRIATIONS.— 
8
There are authorized to be appropriated to carry out 
9
this section— 
10
(A) $75,000,000 for each of fiscal years 
11
2021 and 2022; and 
12
(B) $150,000,000 for each of fiscal years 
13
2023 and 2024. 
14
(2) GIFTS, GRANTS, AND OTHER DONATIONS TO 
15
FOUNDATION.— 
16
(A) ACCEPTANCE.—Pursuant to section 
17
499(c) of the Public Health Service Act (42 
18
U.S.C. 290b(c)), the Foundation for the Na-
19
tional Institutes of Health may solicit and ac-
20
cept gifts, grants, and other donations, estab-
21
lish accounts, and invest and expend funds in 
22
support of carrying out this section. 
23
(B) USE.—In addition to the amounts 
24
made available pursuant to the authorizations 
25
20:05 Jun 20, 2020
H7071
5 
•HR 7071 IH
of appropriations in paragraph (1), the Director 
1
may use, without further appropriation, any 
2
funds derived from a gift, grant, or other dona-
3
tion accepted pursuant to subparagraph (A). 
4
(f) REVIEW AND EXPANSION.—Not later than 18 
5
months after the date of the enactment of this Act— 
6
(1) the Secretary of Health and Human Serv-
7
ices shall convene an independent review panel that 
8
includes representatives of patients, researchers, 
9
drug sponsors, and government agencies; and 
10
(2) the independent review panel shall submit 
11
to the Committee on Energy and Commerce of the 
12
House of Representatives and the Committee on 
13
Health, Education, Labor, and Pensions of the Sen-
14
ate a report on the findings and conclusions of the 
15
panel with respect to the design and implementation 
16
of the program under this section for 2023 and 
17
2024. 
18
SEC. 
3. 
FDA 
CENTER 
OF 
EXCELLENCE 
FOR 
19
NEURODEGENERATIVE DISEASES. 
20
Chapter X of the Federal Food, Drug, and Cosmetic 
21
Act (21 U.S.C. 391 et seq.) is amended by adding at the 
22
end the following: 
23
20:05 Jun 20, 2020
H7071
6 
•HR 7071 IH
‘‘SEC. 
1015. 
CENTER 
OF 
EXCELLENCE 
FOR 
1
NEURODEGENERATIVE DISEASES. 
2
‘‘(a) ESTABLISHMENT.—Not later than September 
3
2021, the Secretary shall establish within the Food and 
4
Drug Administration a center of excellence, to be known 
5
as the Center of Excellence for Neurodegenerative Dis-
6
eases (in this section referred to as the ‘Center of Excel-
7
lence’). 
8
‘‘(b) DUTIES AND AUTHORITIES.—The Center of Ex-
9
cellence shall have duties and authorities similar to those 
10
of the Center of Excellence for Oncology established under 
11
section 1014, including the duties and authorities of the 
12
Center of Excellence for Oncology with respect to Project 
13
Facilitate.’’. 
14
Æ 
20:05 Jun 20, 2020
H7071
